Rare mutations at EGFR L747 position: molecular characteristics and superior response to afatinib in NSCLC patients [0.03%]
EGFR L747位点罕见突变的分子特征及对肺腺癌患者阿法替尼治疗更优疗效的研究
Y Huang,L Pang,J Lao et al.
Y Huang et al.
Background: Little is known about the molecular characteristics and responses to different therapies in missense mutations at epidermal growth factor receptor (EGFR) L747 position (EGFR L747X) due to their low prevalence ...
FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling [0.03%]
整合基因组和免疫组化分析鉴定出FGFR1拷贝数扩增的结直肠癌独特亚型
X Lyu,R Cai,B Han et al.
X Lyu et al.
Background: Fibroblast growth factor receptor (FGFR) alterations are established therapeutic targets in cholangiocarcinoma and urothelial carcinoma but remain understudied in colorectal cancer (CRC). This study investigat...
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292) [0.03%]
绝经后HR阳性HER2阴性早期乳腺癌内分泌治疗反应评估:WSG ADAPTcycle研究中局部与中央Ki67检测结果一致性分析(n=5292)
M Hamann,M Christgen,O Gluz et al.
M Hamann et al.
Background: Low post-endocrine Ki67 (Ki67post) as a marker for endocrine therapy response (ETR) has been shown to be a favorable prognostic factor in hormone receptor (HR)-positive/human epidermal growth factor receptor 2...
Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers [0.03%]
携带BRCA基因的年轻乳腺癌患者妊娠后的安全性分析
M Perachino,E Blondeaux,V Delucchi et al.
M Perachino et al.
Background: For women carrying a germline pathogenic or likely pathogenic variant in the BRCA1/2 genes, having a pregnancy following breast cancer diagnosis and treatment is safe. However, no evidence exists on the safety...
Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement [0.03%]
肿瘤学早期临床试验中筛查失败的应对:对患者预后及改善策略的影响
I Korakis,K Ouali,B Hanvic et al.
I Korakis et al.
Background: Early-phase trials (EPT) assess efficacy/safety of new drugs that may represent therapeutic opportunities. Considering the stringent eligibility criteria, the screening process can result in high rate of scree...
Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approaches [0.03%]
区分低肿瘤负荷和结直肠癌寡转移性疾病的个体化治疗呼吁
M C de Grandis,I Baraibar,O Prior et al.
M C de Grandis et al.
Metastatic colorectal cancer (mCRC) remains a major clinical challenge; however, tumor burden significantly influences treatment outcomes. In this review, we explore the biological and clinical relevance of low tumor burden (LTB) in mCRC. T...
The immunologic landscape of HRAS-mutant head and neck squamous-cell carcinoma [0.03%]
HRAS突变型头颈鳞癌的免疫图谱
P Economopoulou,T Rampias,A Spathis et al.
P Economopoulou et al.
Background: HRAS mutations define a distinct biologic subset of head and neck squamous-cell carcinoma (HNSCC). There are limited data regarding HRAS-mutant (mut) tumors' sensitivity to immunotherapy. We sought to evaluate...
Letter re: The efficacy of immunotherapy combined with capecitabine versus immunotherapy alone as maintenance therapy in patients with de novo metastatic nasopharyngeal carcinoma: a retrospective propensity score matching study [0.03%]
关于免疫治疗联合卡培他滨与单用免疫治疗作为新发转移性鼻咽癌维持治疗有效性的信:一项回顾性倾向评分匹配研究
T K Sahin,D C Guven
T K Sahin
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma [0.03%]
EV-302期III全球研究探索性亚组分析:恩Fortumab Vedotin联合帕博利珠单抗对比化疗治疗未接受过治疗的局部晚期或转移性尿路上皮癌
M S van der Heijden,T Powles,S Gupta et al.
M S van der Heijden et al.
Background: In the phase III EV-302 study (NCT04223856), enfortumab vedotin (EV) plus pembrolizumab (P) demonstrated superior efficacy and safety versus platinum-based chemotherapy in patients with previously untreated lo...
Impact of clonal hematopoiesis on cardiovascular outcomes in cancer patients of the UK Biobank [0.03%]
英国生物样本库中克隆型血液细胞增多对癌症患者心血管预后的影响
M Sun,L Busque,J Sandoval et al.
M Sun et al.
Background: Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) have been linked to increased risks of cardiovascular disease (CVD) and mortality. CHIP and mCAs may also then c...